Merck Kicks Off Human Covid-19 Vaccine Trial In Belgium- Report

Merck & Co. (MRK) has now started testing its experimental Covid-19 vaccine candidate V591 in healthy volunteers, according to a report from the Wall Street Journal.The Phase 1 / 2 trial, which will take place in Belgium with 260 enrolled subjects, was reported by Merck on a government database and confirmed by the company, says the Wall Street Journal.According to the publisher, Merck said that dosing in study subjects has begun, but did not provide further comment.Merck gained the rights to V591 via its May acquisition of Themis, an Austrian vaccine maker developing vaccines and therapies based on an innovative …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.